hrp0086p2-p269 | Diabetes P2 | ESPE2016

Which Group of Children Achieved the Best Results During Insulin Pump Therapy – Long-term Outcome in Children with Type 1 Diabetes?

Ben-Skowronek Iwona , Piekarski Robert , Wysocka Beata , Bury Anna , Banecka Bozena , Krzewska Aleksandra , Sieniawska Joanna , Kabat Magdalena , Rebowicz Katarzyna , Osiak Wiktoria , Szewczyk Leszek

Background: CSII has some potential advantages and disadvantages for young children. For many young patients, it is easier and more convenient to take multiple daily doses of insulin with CSII than with a syringe or insulin pen.Objective and hypotheses: The growing popularity of type 1 diabetes (DM1) treatment based on continuous subcutaneous insulin infusion (CSII) raises a question of the group of patients that benefit most from the treatment.<p cl...

hrp0097p1-321 | Growth and Syndromes | ESPE2023

Questionnaire concerning the process of puberty induction among patients with Turner Syndrome

Więcek Małgorzata , Kempińska Wiktoria , Smyth Alene , Gawlik Aneta

Introduction: Characteristics of the Turner syndrome (TS) include congenital gonadal dysgenesis resulting in disturbed sexual maturation. Only 20 % of patients with TS menstruate spontaneously. In most cases pharmacological puberty induction is required to maintain female secondary sex characteristics and menarche. Preferred age of start of estrogen replacement is between 11 and 12 years with gradual increase of dose during 2–3 years.<p class="abstex...

hrp0094p2-139 | Diabetes and insulin | ESPE2021

Different schemes of insulin therapy (CSII and MDII) in children with DM1 in a Dnipro city.

Yenhovatova Viktoria , Zelinska Nataliya , Globa Evgenia ,

Background: Due to the Ukrainian Pediatric Diabetes Register (UPDR) the number of children with DM1 0-17 y.o. in 2019 was 9860 (1 in 769), with Dm2 36 (1 in 210,547) with neonatal DM (NDM) 66 (1 in 115,000), with MODY 40 cases (1 in 114,844). The diabetes prevalence rates increased from 9.3 (per 1000) in 2007 up to 12,57 (per 1000) in 2018. CSII is well established in pediatric patients with DM1. Most studies focus on such parameters as HbA1c levels...

hrp0097p1-234 | Diabetes and Insulin | ESPE2023

Health services for children with diabetes mellitus in Dnipro, Ukraine

Yenhovatova Viktoria , Globa Evgenia , Zelinska Natalia

As of 2022, the Ukraine Pediatric Diabetes Register (UPDR) contained children aged <18 years with DM1- 11014 (1 in 677), with DM2 – 51 (1 in 146274), with neonatal diabetes (ND) – 69 (1 in 108115), and 59 cases (1 in 126440) with MODY. Most studies focus on such parameters as HbA1c, acute complications and quality of life, whereas investigations of the frequency of chronic DM1 complications and glycemic control for internally displaced persons (IDP) have not bee...

hrp0089p3-p261 | Growth &amp; Syndromes P3 | ESPE2018

Leri-Weill Syndrome Phenotype with Atypical Cytogenetic Finding

Mladenov Vilhelm , Iotova Violeta , Angelova Lydmila , Stoyanova Milena , Bogdanova Viktoria

Introduction: Leri-Weill dyschondrosteosis (LWD) is caused by haploinsufficiency of the SHOX gene, located in the pseudoautosomal region (PAR 1) of the short arm of the X and Y chromosomes. The gene is expressed in highest levels in bone tissue and its product likely controls the chondrocyte apoptosis. Deletions and duplications are most frequent, point mutations are responsible for minority of the cases. The main clinical symptoms of LWD include disproportionate short stature...

hrp0094p2-169 | Diabetes and insulin | ESPE2021

Case of HNF1B MODY

Yenhovatova Viktoria , Zelinska Nataliya , Globa Evgenia , Patel Kashyap ,

Background: MODY HNF1B variants are most frequently associated with extra-pancreatic manifestations like renal cysts [leading to renal cysts and diabetes (RCAD) syndrome], abnormalities of the uro-genital tract and hypomagnesemia, but may also cause MODY or renal structural disease in isolation, therefore cases of HNF1B MODY still remained largely undiagnosed. In Ukraine, there are currently three patients with MODY HNF1B de novo who...

hrp0094p2-411 | Sex differentiation, gonads and gynaecology or sex endocrinology | ESPE2021

Rationale for a reduced dexamethasone dose in prenatal congenital adrenal hyperplasia therapy based on pharmacokinetic modelling

Neumann Uta , Stachanow Viktoria , Blankenstein Oliver , Fuhr Uwe , Huisinga Wilhelm , Reisch Nicole , Kloft Charlotte

Context: Prenatal dexamethasone (Dex) therapy is used in female foetuses with congenital adrenal hyperplasia (CAH) to suppress adrenal androgen excess and prevent virilisation of the external genitalia. The prenatal dexamethasone dose of 20 µg/kg/d has been used for decades in prenatal CAH. Despite the risks for the treated mother and potentially for the unborn child, no clinical study or evaluation had been conducted in order to determine a Dex dose with a scientific rat...